Cyanovirin variant-polymer conjugates

Details Cyanovirin variant-polymer conjugates Cyanovirin variant-polymer conjugates

2007-09-11

2007-09-11

Campell, Bruce R. (Department: 1648)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving virus or bacteriophage

C435S068100, C435S071100, C424S009340, C424S134100

Reexamination Certificate

active

10742465

ABSTRACT:
The present invention provides variants of cyanovirin-N and water-soluble polymer conjugates thereof. The cyanovirin-N of the invention are particularly suited for site-selective covalent attachment of one or more water soluble polymers, to provide polymer conjugates of cyanovirin-N variants exhibiting antiviral activity.

REFERENCES:
patent: 5766897 (1998-06-01), Braxton
patent: 2002/0127675 (2002-09-01), Boyd
patent: WO 02/077189 (2002-10-01), None
patent: WO 03/066078 (2003-08-01), None
French et al., What is Conservative Substitution, 1983, Journal of Molecular Evolution vol. 16, pp. 171-175.
Sigma-Aldrich, www.sigmaaldrich.com, Product=Polyethylene glycol, 1997.
Copy of International Search report from PCT/US03/40585 filed on Dec. 18, 2003.
Roberts, M.J. et al., “Chemistry for peptide and protein PEGylation”,Advanced Drug Delivery Reviews54(4):459-476, 2002.
Goodson, R. J. et al., “Site-Directed Pegylation of Recombinant Interleukin-2 at Its Glycosylation Site”,Bio/Technology8:343-346, 1990.
O'Keefe, B. et al., “Analysis of the Interaction Between the HIV-Inactivating Protein Cyanovirin-N and Soluble Forms of the Envelope Glycoproteins gp120 and gp41”,Molevular Pharmacology58(5):982-992.
Mori, T. et al., “Functional homologs of cyanovirin-N amenable to mass production in prokaryotic and eurokaryotic hosts”,Protein Expression and Purification, 26(1):42-49, 2002.
Botos, I. et al., “Domain-swapped structure of a mutant of cyanovirin-N”,Biochemical and Biophysical Research Communications, 294(1):184-190, 2002.
Botos, I. et al., “Structures of the Complexes of a Potent Anti-HIV Protein Cyanovirin-N and High Mannose Oligosaccharides”,The Journal of Biological Chemistry, 277(37): 34336-34342, Sep. 13, 2002.
Shenoy, S. R. et al., “Selective Interactions of the Human Immunodeficiency Virus-Inactivating Protein Cyanovirin-N with High-Mannose Oligosaccharides on gp120 and Other Glycoproteins”,The Journal of Pharmacology and Experimental Therapeutics, 197(2):704-710, 2001.
Han, Z.Z. et al., “Discovery of a Stable Dimeric Mutant of Cyanovirin-N (CV-N) froma T7 Phage-Displayed CV-N Mutant Library”,Biochemical and Biophysical Research Communications, 292(4):1036-1043, Apr. 12, 2002.
Bewley, C.A., “Solution Structure of a Cyanovirin-N:Manα 1-2Manα Complex: Structural Basis for High-Affinity Carbohydrate-Mediated Binding to gp120”,Structure(Camb.) 9(10):931-940, Oct. 2001.
Bewley, C.A. and Otero-Quintero, S., The Potent Anti-HIV Protein Cyanovirin-N Contains Two Novel Carbohydrate Binding Sites That Selectively Bind to Man8D1D3 and Man9with Nanomolar Affinity: Implications for Binding to the HIV Envelope Protein gp120,Journal of Amer. Chem. Soc.123(17):3892-3902, May 2, 2001.
Bewley, C.A., “Rapid Validation of the Overall Structure of an Internal Domain-Swapped Mutant of the Anti-HIV Proten Cyanovirin-N using Residual Dipolar Couplings”,Journal of Amer. Chem. Soc.123(5):1014-1015, Feb. 7, 2001.
Gandhi, M.J. et al., “Properties of Cyanovirin-N (CV-N): Inactivation of HIV-1 by Sessile Cyanovirin-N (sCV-N)”,Advances in Transfusion Safety, Dev. Biol. Stand.102:141-148, 2000.
Bewley, C.A., et al., “Solution structure of cyanovirin-N, a potent HIV-inactivating protein”,Nature Structural Biology5(7):571-578, Jul. 1998.
Mori, T. et al., Analysis of Sequence Requirement for Biological Activity of Cyanovirin-N, a Potent HIV (Human Immunodeficiency Virus)-Inactivating Protein1,2n,Biochemical and Biophysical Research Communications238(1):218-222, Sep. 8, 1997.
Boyd, M.R. et al., “Discovery of Cyanovirin-N, a Novel Human Immunodeficiency Virus-Inactivating Protein That Binds Viral Surface Envelope Glycoprotein gp120: Potential Applications to Microbicide Development”,Antimicrobial Agents and Chemotherapy, 41(7):1521-1530, Jul. 1997.
Chang, L.C. and Bewley, C. A., “Potent Inhibition of HIV-1 Fusion by Cyanovirin-N Requires Only a Single high Affinity Carbohydrate Binding Site: Characterization of Low Affinity Carbohydrate Binding Site Knockout Mutants”,J. Mol. Biol., 318:1-8, Apr. 19, 2002.

Affiliated with

Also associated with

Rating

Cyanovirin variant-polymer conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyanovirin variant-polymer conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyanovirin variant-polymer conjugates will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3769855